Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
55.61
-0.43 (-0.77%)
At close: Sep 26, 2025, 4:00 PM EDT
55.79
+0.18 (0.32%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$634,901
Profits / Employee
$226,061
Market Cap
242.68B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
Dec 31, 2019 | 43,258 | 56 | 0.13% |
Dec 31, 2018 | 43,202 | 520 | 1.22% |
Dec 31, 2017 | 42,682 | 711 | 1.69% |
Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
Dec 31, 2015 | 40,638 | -319 | -0.78% |
Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
Dec 31, 2003 | 18,756 | 751 | 4.17% |
Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
Dec 31, 1999 | 11,994 | 345 | 2.96% |
Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NVO News
- 1 day ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 1 day ago - Novo Nordisk: Wegovy Sales Soar, Trump Tariffs No Threat - Seeking Alpha
- 2 days ago - DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025 - GlobeNewsWire
- 2 days ago - Denmark's 'Novo Town' holds its breath as Wegovy fever fades - Reuters
- 6 days ago - Here Are 2 Defensive Positions That Are Worth A Look Now - Seeking Alpha
- 6 days ago - Ozempic's Maker Got Crushed. The Rebound Is Under Way. - WSJ
- 8 days ago - Novo Nordisk: Don't Be Deterred By Outlook Downgrades - Seeking Alpha
- 8 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - GlobeNewsWire